MPM closes $400M BioVentures 2018 fund

MPM Capital closed BioVentures 2018 at $400 million to fund early stage biotechs. BioVentures 2018, the firm's seventh fund, will invest in therapeutic areas including oncology, immunology and neuroscience, as well as in modalities such as cell, gene and nucleic acid therapies...